# Safety and Tolerability Study of Metadoxine Extended Release (MDX) (Previously Known as MG01CI) in PI-ADHD Adolescent Subjects

> **NCT02189772** · PHASE2 · COMPLETED · sponsor: **Alcobra Ltd.** · enrollment: 83 (actual)

## Conditions studied

- ADHD, Predominantly Inattentive Type

## Interventions

- **DRUG:** Metadoxine extended release
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02189772
- **Lead sponsor:** Alcobra Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2015-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02189772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02189772, "Safety and Tolerability Study of Metadoxine Extended Release (MDX) (Previously Known as MG01CI) in PI-ADHD Adolescent Subjects". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02189772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*